Does the media prefer LXRX or SABS?

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.40 beat SAB Biotherapeutics' score of 1.21 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPK or SABS?

In the previous week, OPKO Health had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for OPKO Health and 5 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.21 beat OPKO Health's score of 0.66 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SABS or GERN?

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Geron. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for Geron. SAB Biotherapeutics' average media sentiment score of 1.21 beat Geron's score of 0.63 indicating that SAB Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RIGL or SABS?

In the previous week, SAB Biotherapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 2 mentions for Rigel Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 1.21 beat Rigel Pharmaceuticals' score of 0.93 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SABS or IRWD?

In the previous week, SAB Biotherapeutics had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.81 beat SAB Biotherapeutics' score of 1.21 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SAB Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

SAB Biotherapeutics (SABS) Competitors

$3.51 -0.07 (-1.96%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.51 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

SAB Biotherapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. SAB Biotherapeutics' return on equity of -0.29% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SAB Biotherapeutics has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$69.64M	14.61	-$50.34M	-$0.07	N/A
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A

Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, indicating a potential upside of 98.69%. SAB Biotherapeutics has a consensus price target of $12.00, indicating a potential upside of 241.88%. Given SAB Biotherapeutics' higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.40 beat SAB Biotherapeutics' score of 1.21 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexicon Pharmaceuticals and SAB Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does SAB Biotherapeutics compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

OPKO Health has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

SAB Biotherapeutics has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.52	-$225.68M	-$0.27	N/A
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. SAB Biotherapeutics' return on equity of -0.29% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 27.05%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 241.88%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, OPKO Health had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 7 mentions for OPKO Health and 5 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.21 beat OPKO Health's score of 0.66 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SAB Biotherapeutics beats OPKO Health on 9 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Geron?

SAB Biotherapeutics (NASDAQ:SABS) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

SAB Biotherapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Geron has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Geron. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 3 mentions for Geron. SAB Biotherapeutics' average media sentiment score of 1.21 beat Geron's score of 0.63 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 7.4% of SAB Biotherapeutics shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SAB Biotherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 241.88%. Geron has a consensus price target of $4.00, suggesting a potential upside of 181.69%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

SAB Biotherapeutics has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A
Geron	$183.88M	4.95	-$83.50M	-$0.11	N/A

SAB Biotherapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. SAB Biotherapeutics' return on equity of -0.29% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Geron	-35.48%	-23.31%	-10.08%

Summary

SAB Biotherapeutics beats Geron on 11 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$299.77M	2.27	$367.02M	$18.72	1.96
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A

In the previous week, SAB Biotherapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 2 mentions for Rigel Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 1.21 beat Rigel Pharmaceuticals' score of 0.93 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 48.34%. SAB Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 241.88%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Rigel Pharmaceuticals has a net margin of 121.50% compared to SAB Biotherapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

Rigel Pharmaceuticals beats SAB Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

SAB Biotherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 241.88%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 68.01%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe SAB Biotherapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71

SAB Biotherapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -0.29% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Ironwood Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A
Ironwood Pharmaceuticals	$296.15M	2.04	$24.02M	$0.60	6.18

In the previous week, SAB Biotherapeutics had 3 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for SAB Biotherapeutics and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.81 beat SAB Biotherapeutics' score of 1.21 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SAB Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

7.8% of SAB Biotherapeutics shares are owned by institutional investors. 7.4% of SAB Biotherapeutics shares are owned by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats SAB Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$268.39M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.66	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	10.48	157.90	50.54	59.64
Price / Book	1.10	7.88	10.28	6.07
Net Income	$13.27M	$23.86M	$3.60B	$331.99M
7 Day Performance	-0.85%	-3.82%	-1.27%	-0.63%
1 Month Performance	-9.30%	-2.61%	-0.37%	-2.00%
1 Year Performance	37.65%	32.79%	18.30%	13.62%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	3.0629 of 5 stars	$3.51 -2.0%	$12.00 +241.9%	+35.0%	$268.39M	N/A	N/A	140	News Coverage Positive News Analyst Upgrade
LXRX Lexicon Pharmaceuticals	1.951 of 5 stars	$2.12 -2.3%	$4.55 +114.6%	+102.7%	$963.91M	$49.80M	N/A	140	News Coverage Positive News Analyst Upgrade
OPK OPKO Health	1.8659 of 5 stars	$1.22 -0.8%	$1.55 +27.0%	-12.9%	$928.76M	$606.90M	N/A	1,373	News Coverage Upcoming Earnings
GERN Geron	2.299 of 5 stars	$1.38 -2.8%	$4.00 +189.9%	+10.9%	$910.96M	$183.88M	N/A	70	Analyst Downgrade
RIGL Rigel Pharmaceuticals	4.0957 of 5 stars	$41.17 -0.3%	$54.50 +32.4%	+79.8%	$764.14M	$294.28M	2.20	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to OPKO Health?

Summary

How does SAB Biotherapeutics compare to Geron?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, OPK, GERN, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Is LXRX or SABS more profitable?

Do insiders and institutionals have more ownership in LXRX or SABS?

Which has better valuation and earnings, LXRX or SABS?

Which has more risk & volatility, LXRX or SABS?

Do analysts recommend LXRX or SABS?

Does the media prefer LXRX or SABS?

Summary

How does SAB Biotherapeutics compare to OPKO Health?

Which has more volatility and risk, OPK or SABS?

Which has preferable valuation & earnings, OPK or SABS?

Is OPK or SABS more profitable?

Do analysts recommend OPK or SABS?

Do institutionals and insiders have more ownership in OPK or SABS?

Does the media prefer OPK or SABS?

Summary

How does SAB Biotherapeutics compare to Geron?

Which has more risk and volatility, SABS or GERN?

Does the media favor SABS or GERN?

Do insiders and institutionals have more ownership in SABS or GERN?

Do analysts rate SABS or GERN?

Which has better valuation & earnings, SABS or GERN?

Is SABS or GERN more profitable?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Do insiders & institutionals believe in RIGL or SABS?

Which has stronger valuation and earnings, RIGL or SABS?

Does the media refer more to RIGL or SABS?

Which has more risk and volatility, RIGL or SABS?

Do analysts prefer RIGL or SABS?

Is RIGL or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Do analysts rate SABS or IRWD?

Which has more volatility and risk, SABS or IRWD?

Is SABS or IRWD more profitable?

Which has better valuation and earnings, SABS or IRWD?

Does the media refer more to SABS or IRWD?

Do insiders & institutionals believe in SABS or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools